2019 current investors include

Alpha Blue Ocean
Apollo Ventures 300x
AV8 Ventures
pontifax
Seventure Partners
DDF Ventures
Science to business
Kreos Capital
Harbert Management Corporation-1
cascara ventures-2
IPF Partners
Xeraya Capital 300x
UCB Pharma 300x
Midven-1
Longwall Ventures-1
Juvenescence 300x-1
Orbimed 300x
Inkef Capital-2
Endeavour 300x
Thuja 300x
GL Capital-1
catapult ventures
Bioscience Managers-1
Ignite Venture
Rainbow Seed Fund Square
Hermes Partners-1
Norgine
Epidarex Capital
Seroba
Albion Capital-1
Gilde Healthcare-1
Novo Ventures-1
Alsa
Illumina Ventures-1
BioSeed Capital-1
Merck Ventures
Sofinnova Partners 300x-1
Wellington Partners-1
Inkef Capital 300x-1
Medicxi 300x-1
Sanofi Ventures 300x-1
Spark Impact 300x
Bridge Valley Ventures
Debere Capital
Kinled 300x
Arterial 300x200
R-Pharm 300x
Panakes Partners 300x
NCL Tech Ventures
Vesalius Biocapital-1
Mercia 300x-1
Panacea 300x
Epidarex Capital
Oxford 300x-1
Gilde Healthcare-1
High-Tech Gründerfonds 300x
Enterprise Ireland 300x
SOSV 300x
aMoon 300x
Kissei 300x
JPIF 300x
Lundbeckfonden 300x
New Wave Ventures-1
Advent 300x
4Bio Capital-1
Biomed Partners-1
Downing-1
Novo Ventures-1
Ventac Partners
simcere-pharmaceutical-group
novateur
Vulpes
Breed Reply
IP Group 300x
QBN Capital
Amaedus Capital
Kurma Partners
Pueros Bioventures
Parkwalk Advisors
Cambridge Innovation Capital
IQ Capital
CTI Life Sciences
wharton asset management
Science to business-1

 

DOWNLOAD BROCHURE